Novel Faces of Fibroblast Growth Factor 23 (FGF23): Iron Deficiency, Inflammation, Insulin Resistance, Left Ventricular Hypertrophy, Proteinuria and Acute Kidney Injury

Mehmet Kanbay, Marc Vervloet, Mario Cozzolino, Dimitrie Siriopol, Adrian Covic, David Goldsmith, Yalcin Solak

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

FGF23 is a hormone that appears as the core regulator of phosphate metabolism. Great deal of data has accumulated to demonstrate increased FGF23 secretion from the bone to compensate for even subtle increases in serum phosphorus long before intact PTH. However, recent evidence points to the fact that actions and interactions of FGF23 are not limited solely to phosphate metabolism. FGF23 may be implicated in iron metabolism and erythropoiesis, inflammation, insulin resistance, proteinuria, acute kidney injury and left ventricular hypertrophy. In this review, we will summarize latest experimental and clinical data examining impact of FGF23 on aforementioned pathophysiologic pathways/disorders.

Original languageEnglish
Pages (from-to)217-228
Number of pages12
JournalCalcified Tissue International
Volume100
Issue number3
DOIs
Publication statusPublished - 1 Mar 2017

Cite this

Kanbay, Mehmet ; Vervloet, Marc ; Cozzolino, Mario ; Siriopol, Dimitrie ; Covic, Adrian ; Goldsmith, David ; Solak, Yalcin. / Novel Faces of Fibroblast Growth Factor 23 (FGF23) : Iron Deficiency, Inflammation, Insulin Resistance, Left Ventricular Hypertrophy, Proteinuria and Acute Kidney Injury. In: Calcified Tissue International. 2017 ; Vol. 100, No. 3. pp. 217-228.
@article{89420f8d6b6d47ae8da243993322407e,
title = "Novel Faces of Fibroblast Growth Factor 23 (FGF23): Iron Deficiency, Inflammation, Insulin Resistance, Left Ventricular Hypertrophy, Proteinuria and Acute Kidney Injury",
abstract = "FGF23 is a hormone that appears as the core regulator of phosphate metabolism. Great deal of data has accumulated to demonstrate increased FGF23 secretion from the bone to compensate for even subtle increases in serum phosphorus long before intact PTH. However, recent evidence points to the fact that actions and interactions of FGF23 are not limited solely to phosphate metabolism. FGF23 may be implicated in iron metabolism and erythropoiesis, inflammation, insulin resistance, proteinuria, acute kidney injury and left ventricular hypertrophy. In this review, we will summarize latest experimental and clinical data examining impact of FGF23 on aforementioned pathophysiologic pathways/disorders.",
keywords = "Acute kidney injury, Fibroblast growth factor 23, Inflammation, Insulin resistance, Left ventricular hypertrophy, Proteinuria",
author = "Mehmet Kanbay and Marc Vervloet and Mario Cozzolino and Dimitrie Siriopol and Adrian Covic and David Goldsmith and Yalcin Solak",
year = "2017",
month = "3",
day = "1",
doi = "10.1007/s00223-016-0206-7",
language = "English",
volume = "100",
pages = "217--228",
journal = "Calcified Tissue International",
issn = "0171-967X",
publisher = "Springer New York",
number = "3",

}

Novel Faces of Fibroblast Growth Factor 23 (FGF23) : Iron Deficiency, Inflammation, Insulin Resistance, Left Ventricular Hypertrophy, Proteinuria and Acute Kidney Injury. / Kanbay, Mehmet; Vervloet, Marc; Cozzolino, Mario; Siriopol, Dimitrie; Covic, Adrian; Goldsmith, David; Solak, Yalcin.

In: Calcified Tissue International, Vol. 100, No. 3, 01.03.2017, p. 217-228.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - Novel Faces of Fibroblast Growth Factor 23 (FGF23)

T2 - Iron Deficiency, Inflammation, Insulin Resistance, Left Ventricular Hypertrophy, Proteinuria and Acute Kidney Injury

AU - Kanbay, Mehmet

AU - Vervloet, Marc

AU - Cozzolino, Mario

AU - Siriopol, Dimitrie

AU - Covic, Adrian

AU - Goldsmith, David

AU - Solak, Yalcin

PY - 2017/3/1

Y1 - 2017/3/1

N2 - FGF23 is a hormone that appears as the core regulator of phosphate metabolism. Great deal of data has accumulated to demonstrate increased FGF23 secretion from the bone to compensate for even subtle increases in serum phosphorus long before intact PTH. However, recent evidence points to the fact that actions and interactions of FGF23 are not limited solely to phosphate metabolism. FGF23 may be implicated in iron metabolism and erythropoiesis, inflammation, insulin resistance, proteinuria, acute kidney injury and left ventricular hypertrophy. In this review, we will summarize latest experimental and clinical data examining impact of FGF23 on aforementioned pathophysiologic pathways/disorders.

AB - FGF23 is a hormone that appears as the core regulator of phosphate metabolism. Great deal of data has accumulated to demonstrate increased FGF23 secretion from the bone to compensate for even subtle increases in serum phosphorus long before intact PTH. However, recent evidence points to the fact that actions and interactions of FGF23 are not limited solely to phosphate metabolism. FGF23 may be implicated in iron metabolism and erythropoiesis, inflammation, insulin resistance, proteinuria, acute kidney injury and left ventricular hypertrophy. In this review, we will summarize latest experimental and clinical data examining impact of FGF23 on aforementioned pathophysiologic pathways/disorders.

KW - Acute kidney injury

KW - Fibroblast growth factor 23

KW - Inflammation

KW - Insulin resistance

KW - Left ventricular hypertrophy

KW - Proteinuria

UR - http://www.scopus.com/inward/record.url?scp=84994442826&partnerID=8YFLogxK

U2 - 10.1007/s00223-016-0206-7

DO - 10.1007/s00223-016-0206-7

M3 - Review article

VL - 100

SP - 217

EP - 228

JO - Calcified Tissue International

JF - Calcified Tissue International

SN - 0171-967X

IS - 3

ER -